$\blacksquare MS \blacksquare N A R C > MS$

The Profile of a Contemporary Cohort of Participants with Primary Progressive Multiple Sclerosis in the NARCOMS Registry

A Salter, N Thomas, G Cutter, RA Marrie, T Tyry

The 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers National Harbor, MD, USA, June 1-4, 2016 Oral Presentation CC01

Disclosures

Amber Salter has nothing to disclose.


Nina Thomas is an employee of Genentech, Inc.

Ruth Ann Marrie (last two years): Pharma-funded research: Sanofi-Aventis; Other sources of research funding: CIHR, PHAC, National Multiple Sclerosis Society, MS Society of Canada, MS Scientific Foundation, CMSC Foundation, Rx & D Health Research Foundation.

Gary R. Cutter serves on data safety monitoring committees for Antisense Therapeutics Limited, Sanofi-Aventis, Bayhill Pharmaceuticals, Bayer Pharmaceuticals, BioMS Pharmaceuticals, Daichi-Sankyo, Glaxo Smith Klein Pharmaceuticals, Genmab Biopharmaceuticals, Medivation, Peptimmune, PTC Therapeutics, Teva, Vivus, NHLBI, NINDS, National MS Society: and receives consulting or speaking fees from Alexion, Accentia, Barofold, CibaVision, Biogen-Idec, Novartis, Consortium of MS Centers, Klein-Buendel Incorporated, Enzo Pharmaceuticals, Somnus Pharmaceuticals, Teva, Biogen Idec, Advanced Health Media, EMD Serono, EDJ Associates, Aegis Creative Marketing, Eli Lilly, UT Southwestern University, Klein Buendel, University of Illinois Health Policy Center, Somnus Therapeutics.

Tuula Tyry has nothing to disclose.

NARCOMS is supported in part by the Consortium of MS Centers and its Foundation. This study was funded in part by Genentech, Inc. Support for third-party writing assistance was provided by Genentech, Inc. and furnished by Articulate Science and Health Interactions.



Study objectives and survey distribution

Study objectives

•To describe the demographic and clinical characteristics of NARCOMS participants who self-identified as having PPMS

Survey distribution

•The NARCOMS Registry collects a wide range of self-reported health-related information from participants via semiannual surveys

•The Spring 2015 Update survey had a total of 8,004 respondents


5

6

PPMS, primary progressive multiple sclerosis.

Study inclusion criteria

• Of the 8,004 survey respondents, **632** participants **(7.9%)** who selfreported a PPMS diagnosis were selected for the study



CIS, clinically isolated syndrome; MS, multiple sclerosis; PPMS, primary progressive MS; PRMS, progressive-relapsing MS; RRMS, relapsing-remitting MS; SPMS, secondary progressive MS.


Demographics of the PPMS cohort

Characteristics	
Female, n (%)	396 (62.7)
Race, n (%) White Black Other	576 (93.8) 17 (2.8) 21 (3.4)
Age at survey completion, mean (SD), years	64.3 (8.9)
Residence, n (%) Private home/apartment/condo Private home with home health aide Assisted living Nursing home	522 (83.3) 75 (12.0) 12 (1.9) 18 (2.9)
Has health insurance, n (%)	544 (86.1)


Numbers vary slightly across characteristics due to missing values. PPMS, primary progressive multiple sclerosis.

Employment status in the PPMS cohort

• A total of **552** participants **(89%)** from the PPMS cohort were not working for various reasons








PDDS, Patient-Determined Disease Steps; PPMS, primary progressive multiple sclerosis.






The original set of 8 Performance Scales have been copyrighted by Delta-Quest. Copyright Registration Number / Date: TXu000743629 / 1996-04-04;
 assigned to DeltaQuest Foundation, Inc., effective October 1, 2005. U.S. Copyright law governs terms of use.
 PPMS, primary progressive multiple sclerosis; PS, performance scale.

Moderate

(Minimal, Severe)




Bowel and bladder PS1



	Median	(25%, 75%)
Hand PS ¹	Mild	(Minimal, Severe)
Sensory PS ¹	Mild	(Minimal, Mild)
Spasticity PS ¹	Mild	(Minimal, Mild)

 I. The original set of 8 Performance Scales have been copyrighted by Delta-Quest. Copyright Registration Number / Date: TXu000743629 / 1996-04-04; assigned to DeltaQuest Foundation, Inc., effective October 1, 2005. U.S. Copyright law governs terms of use.
PPMS, primary progressive multiple sclerosis; PS, performance scale.

PPMS cohort: Performance Scales





	Median	(25%, 75%)
Vision PS ¹	Minimal	(Normal, Mild)
Cognition PS ¹	Minimal	(Normal, Mild)

 1. The original set of 8 Performance Scales have been copyrighted by Delta-Quest. Copyright Registration Number / Date: TXu000743629 / 1996-04-04;


 assigned to DeltaQuest Foundation, Inc., effective October 1, 2005. U.S. Copyright law governs terms of use.

 PPMS, primary progressive multiple sclerosis; PS, performance scale.






Participants could select all applicable answers



PPMS, primary progressive multiple sclerosis.



MCS, mental component summary; PCS, physical component summary; PPMS, primary progressive multiple sclerosis; QoL, quality of life.

Conclusions

- The NARCOMS Registry includes detailed and current diseaserelated information on several hundred people with PPMS
- The prevalence of PPMS in the self-described MS cohort from the semi-annual Spring 2015 Update survey was almost 8%
- Participants with PPMS reported:
 - A high-level of disability
 - Varying degrees of physical and functional impairment
 - Visits to a range of healthcare providers
 - Multiple comorbidities
 - Off-label use of DMTs
- Further analysis of the available data, along with continued followup, will add to our understanding of this disease type and help address the unmet need in this less researched and less understood form of MS

DMT, disease-modifying therapy; MS, multiple sclerosis; PPMS, primary progressive MS.

Acknowledgments

CMSC NARC SMS

NARCOMS is supported in part by the Consortium of MS Centers and its Foundation. This project was funded in part by Genentech, Inc. 19